PureTech Health (LON:PRTC) Stock Price Up 11.2% - Should You Buy?

Key Points

• PureTech Health shares increased by 11.2% to GBX 118.31 ($1.60) during trading, with a significant trading volume of approximately 1.8 million shares.
• The company has a market capitalization of £285.93 million and a P/E ratio of 695.92, indicating a high valuation relative to its earnings.
• Insider Bharatt Chowrira recently purchased 167,739 shares at GBX 1 per share, suggesting confidence in the company's future performance.

PureTech Health plc (LON:PRTC - Get Free Report) rose 11.2% on Friday . The company traded as high as GBX 119.80 ($1.61) and last traded at GBX 118.31 ($1.59). Approximately 1,802,969 shares changed hands during mid-day trading, an increase of 143% from the average daily volume of 741,926 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Stock Up 14.2%

The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The company has a market capitalization of £293.65 million, a price-to-earnings ratio of 714.71 and a beta of 1.02. The stock's fifty day simple moving average is GBX 129.46 and its two-hundred day simple moving average is GBX 129.76.

Insiders Place Their Bets

In other PureTech Health news, insider Bharatt Chowrira purchased 167,739 shares of the business's stock in a transaction on Thursday, July 3rd. The stock was bought at an average cost of GBX 1 per share, with a total value of £1,677.39. Insiders own 13.13% of the company's stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.